Steep markups on GLP-1s, insulin pens hinder diabetes care: study
2024-03-28
Amid burgeoning global demand for effective diabetes medicines, including GLP-1 agonists like Novo Nordisk's Ozempic (semaglutide) and Eli Lilly's Trulicity (dulaglutide), a new study suggests these treatments are virtually out of reach in low- and middle-income countries due to significant price markups and barriers to generic manufacturing.
The study conducted by Médecins Sans Frontières (MSF) was published this week in JAMA Open Network. Investigators estimated the cost of manufacturing insulins, GLP-1s and SGLT2 inhibitors, then calculated "sustainable" cost-based prices and compared these with current market prices for serval products. The market prices were derived from 13 countries, collected from public databases in January 2023.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。